Details of the Drug

General Information of Drug (ID: DMR6N7H)

Drug Name
Acetohexamide
Synonyms
Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1], [2]
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 324.4
Topological Polar Surface Area (xlogp) 2.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption
The drug is rapidly absorbed from the gastrointestinal tract [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.3 hours [5]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 77.06496 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 3.43 mg/mL [4]
Chemical Identifiers
Formula
C15H20N2O4S
IUPAC Name
1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea
Canonical SMILES
CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2
InChI
InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
InChIKey
VGZSUPCWNCWDAN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1989
ChEBI ID
CHEBI:28052
CAS Number
968-81-0
DrugBank ID
DB00414
TTD ID
D07WFK
VARIDT ID
DR01113
INTEDE ID
DR0039

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ATP-binding cassette transporter C8 (ABCC8) TTP835K ABCC8_HUMAN Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Short-chain dehydrogenase/reductase retSDR1 (DHRS3) DEXPVUN DHRS3_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Acetohexamide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Nateglinide DMLK2QH Moderate Decreased metabolism of Acetohexamide caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [27]
Coadministration of a Drug Treating the Disease Different from Acetohexamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Acetohexamide due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [28]
Tromethamine DMOBLGK Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Acetohexamide caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [29]
Oxandrolone DMU9MYJ Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Oxandrolone. Alcoholic liver disease [DB94] [30]
Oxymetholone DMFXUT8 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Oxymetholone. Aplastic anaemia [3A70] [31]
Voriconazole DMAOL2S Major Decreased metabolism of Acetohexamide caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [30]
Clarithromycin DM4M1SG Moderate Increased plasma concentration of Acetohexamide and Clarithromycin due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [32]
Sulfamethoxazole DMB08GE Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [31]
Chloramphenicol DMFXEWT Moderate Increased plasma concentration of Acetohexamide and Chloramphenicol due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [33]
Linezolid DMGFPU2 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Linezolid. Bacterial infection [1A00-1C4Z] [30]
Nitazoxanide DMOWLVG Moderate Increased plasma concentration of Acetohexamide and Nitazoxanide due to competitive binding of plasma proteins. Bowel habit change [ME05] [34]
Alpelisib DMEXMYK Moderate Increased metabolism of Acetohexamide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Fluoxymesterone. Breast cancer [2C60-2C6Y] [30]
Fenofibric acid DMGO2MC Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [30]
Ketoprofen DMRKXPT Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Ketoprofen. Chronic pain [MG30] [30]
Ardeparin DMYRX8B Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Ardeparin. Coronary thrombosis [BA43] [30]
Mifepristone DMGZQEF Moderate Decreased metabolism of Acetohexamide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [36]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Acetohexamide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [37]
MK-8228 DMOB58Q Moderate Increased metabolism of Acetohexamide caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [38]
Sertraline DM0FB1J Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Sertraline. Depression [6A70-6A7Z] [30]
Fluoxetine DM3PD2C Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Fluoxetine. Depression [6A70-6A7Z] [30]
Vilazodone DM4LECQ Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Vilazodone. Depression [6A70-6A7Z] [30]
Selegiline DM6034S Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Selegiline. Depression [6A70-6A7Z] [30]
Vortioxetine DM6F1PU Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Vortioxetine. Depression [6A70-6A7Z] [30]
Isocarboxazid DMAF1NB Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Isocarboxazid. Depression [6A70-6A7Z] [30]
Escitalopram DMFK9HG Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Escitalopram. Depression [6A70-6A7Z] [30]
Tranylcypromine DMGB5RE Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Tranylcypromine. Depression [6A70-6A7Z] [31]
Phenelzine DMHIDUE Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Phenelzine. Depression [6A70-6A7Z] [30]
PMID28454500-Compound-96 DM2A75P Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and PMID28454500-Compound-96. Discovery agent [N.A.] [30]
SODIUM CITRATE DMHPD2Y Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Acetohexamide caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [29]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and PMID28870136-Compound-49. Discovery agent [N.A.] [30]
Mefenamic acid DMK7HFI Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Mefenamic acid. Female pelvic pain [GA34] [30]
Miconazole DMPMYE8 Major Decreased metabolism of Acetohexamide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [30]
Nizatidine DMGFV3Z Moderate Decreased absorption of Acetohexamide due to altered gastric pH caused by Nizatidine. Gastro-oesophageal reflux disease [DA22] [39]
Cimetidine DMH61ZB Moderate Decreased absorption of Acetohexamide due to altered gastric pH caused by Cimetidine. Gastro-oesophageal reflux disease [DA22] [39]
Sunitinib DMCBJSR Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [30]
Rifampin DMA8J1G Moderate Increased metabolism of Acetohexamide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [40]
Rifapentine DMCHV4I Moderate Increased metabolism of Acetohexamide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [41]
Etravirine DMGV8QU Moderate Decreased metabolism of Acetohexamide caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Gemfibrozil DMD8Q3J Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Gemfibrozil. Hyper-lipoproteinaemia [5C80] [30]
Fenofibrate DMFKXDY Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Fenofibrate. Hyper-lipoproteinaemia [5C80] [30]
Moexipril DM26E4B Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Moexipril. Hypertension [BA00-BA04] [30]
Captopril DM458UM Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Captopril. Hypertension [BA00-BA04] [30]
Trandolapril DM4L6EU Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Trandolapril. Hypertension [BA00-BA04] [30]
Methyldopa DM5I621 Minor Decreased metabolism of Acetohexamide caused by Methyldopa. Hypertension [BA00-BA04] [43]
Fosinopril DM9NJ52 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Fosinopril. Hypertension [BA00-BA04] [30]
Benazepril DMH1M9B Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Benazepril. Hypertension [BA00-BA04] [30]
Enalapril DMNFUZR Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Enalapril. Hypertension [BA00-BA04] [30]
Perindopril DMOPZDT Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Perindopril. Hypertension [BA00-BA04] [30]
Quinapril DMR8H31 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Quinapril. Hypertension [BA00-BA04] [30]
Lisinopril DMUOK4C Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Lisinopril. Hypertension [BA00-BA04] [30]
Sodium acetate anhydrous DMH21E0 Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Acetohexamide caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [29]
Probenecid DMMFWOJ Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [30]
Meclofenamic acid DM05FXR Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [31]
Testosterone DM7HUNW Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Testosterone. Low bone mass disorder [FB83] [30]
PF-06463922 DMKM7EW Moderate Increased metabolism of Acetohexamide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [44]
Chloroquine DMSI5CB Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Chloroquine. Malaria [1F40-1F45] [30]
Hydroxychloroquine DMSIVND Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Hydroxychloroquine. Malaria [1F40-1F45] [30]
Mecasermin DM1O3BY Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Mecasermin. Multiple structural anomalies syndrome [LD2F] [30]
Rifabutin DM1YBHK Moderate Increased metabolism of Acetohexamide caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [40]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Acetohexamide and Methoxsalen. Mycosis fungoides [2B01] [44]
Diclofenac DMPIHLS Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Diclofenac. Osteoarthritis [FA00-FA05] [30]
Naproxen DMZ5RGV Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Naproxen. Osteoarthritis [FA00-FA05] [30]
Dextropropoxyphene DM23HCX Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Dextropropoxyphene. Pain [MG30-MG3Z] [31]
Aspirin DM672AH Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Aspirin. Pain [MG30-MG3Z] [31]
Etodolac DM6WJO9 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Etodolac. Pain [MG30-MG3Z] [30]
Diflunisal DM7EN8I Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Diflunisal. Pain [MG30-MG3Z] [30]
Ibuprofen DM8VCBE Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Ibuprofen. Pain [MG30-MG3Z] [30]
Nabumetone DMAT2XH Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Nabumetone. Pain [MG30-MG3Z] [30]
Piroxicam DMTK234 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Piroxicam. Pain [MG30-MG3Z] [30]
Safinamide DM0YWJC Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Safinamide. Parkinsonism [8A00] [30]
Rasagiline DM3WKQ4 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Rasagiline. Parkinsonism [8A00] [30]
Ranitidine DM0GUSX Moderate Decreased absorption of Acetohexamide due to altered gastric pH caused by Ranitidine. Peptic ulcer [DA61] [39]
Esomeprazole DM7BN0X Minor Decreased metabolism of Acetohexamide caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [45]
Famotidine DMRL3AB Moderate Decreased absorption of Acetohexamide due to altered gastric pH caused by Famotidine. Peptic ulcer [DA61] [39]
Choline salicylate DM8P137 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Choline salicylate. Postoperative inflammation [1A00-CA43] [31]
Ketorolac DMI4EL5 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Ketorolac. Postoperative inflammation [1A00-CA43] [30]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Acetohexamide and Verteporfin. Psoriasis [EA90] [46]
Bosentan DMIOGBU Moderate Increased metabolism of Acetohexamide caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [47]
Salsalate DM13P4C Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Salsalate. Rheumatoid arthritis [FA20] [30]
Meloxicam DM2AR7L Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Meloxicam. Rheumatoid arthritis [FA20] [30]
Sulindac DM2QHZU Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Sulindac. Rheumatoid arthritis [FA20] [30]
Celecoxib DM6LOQU Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Celecoxib. Rheumatoid arthritis [FA20] [30]
Oxaprozin DM9UB0P Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Oxaprozin. Rheumatoid arthritis [FA20] [30]
Flurbiprofen DMGN4BY Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Flurbiprofen. Rheumatoid arthritis [FA20] [30]
Sulfasalazine DMICA9H Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Sulfasalazine. Rheumatoid arthritis [FA20] [30]
Fenoprofen DML5VQ0 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Fenoprofen. Rheumatoid arthritis [FA20] [30]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Acetohexamide caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [48]
Tolmetin DMWUIJE Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Tolmetin. Rheumatoid arthritis [FA20] [30]
Cyclophosphamide DM4O2Z7 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [30]
Ifosfamide DMCT3I8 Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [30]
Methyltestosterone DMWLFGO Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [30]
Pramlintide DM0EZ9Q Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Pramlintide. Type-1/2 diabete [5A10-5A11] [30]
Olsalazine DMZW9HA Moderate Increased risk of hypoglycemia by the combination of Acetohexamide and Olsalazine. Ulcerative colitis [DD71] [30]
⏷ Show the Full List of 93 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6793).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071893.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
8 Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
9 Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 2015 Jun 5;234:178-87.
10 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
11 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
12 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
15 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
16 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
17 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
18 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
20 Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90.
21 Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
22 Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
23 Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9.
24 Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.Metabolism.2004 Apr;53(4):441-7.
25 Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2944).
27 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
28 Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
29 Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
30 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
31 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
32 Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
33 Brunova E, Slabochova Z, Platilova H, Pavlik F, Grafnetterova J, Dvoracek K "Interaction of tolbutamide and chloramphenicol in diabetic patients." Int J Clin Pharmacol 15 (1977): 7-12. [PMID: 838527]
34 Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
35 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
37 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
38 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
39 Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
40 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
41 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
42 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
43 Gachalyi B, Tornyossy, Vas A, Kaldor A "Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man." Int J Clin Pharmacol Ther Toxicol 18 (1980): 133-5. [PMID: 6103880]
44 Cerner Multum, Inc. "Australian Product Information.".
45 Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
46 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
47 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
48 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.